Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Cancer

Update on bone-modifying agents in metastatic breast cancer

Nature Reviews Endocrinology volume 7, pages 380–381 (2011)Cite this article

Subjects

A Correction to this article was published on 22 August 2011

This article has been updated

Advances in the development of bone-modifying agents have led to the approval of new drugs for the prevention and treatment of skeletal-related events in patients with bone metastases from breast cancer. In light of these advances, the American Society of Clinical Oncology has published a guideline update.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Change history

  • 14 July 2011

    In the online and print versions of this article initially published, the name and email address of the corresponding author (L. J. Suva; suvalarryj@uams.edu) were missing. The error has been corrected for the HTML and PDF versions of the article.

References

  1. Suva, L. J., Washam, C., Nicholas, R. W. & Griffin, R. J. Bone metastasis: mechanisms and therapeutic opportunities. Nat. Rev. Endocrinol. 7, 208–218 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Hortobagyi, G. N. et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N. Engl. J. Med. 335, 1785–1791 (1996).

    Article  CAS  PubMed  Google Scholar 

  3. Lipton, A., Cook, R. J., Major, P., Smith, M. R. & Coleman, R. E. Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity. Oncologist 12, 1035–1043 (2007).

    Article  CAS  PubMed  Google Scholar 

  4. Hillner, B. E. et al. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel. J. Clin. Oncol. 18, 1378–1391 (2000).

    Article  CAS  PubMed  Google Scholar 

  5. Hillner, B. E. et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J. Clin. Oncol. 21, 4042–4057 (2003).

    Article  CAS  PubMed  Google Scholar 

  6. Van Poznak, C. H. et al. American society of clinical oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J. Clin. Oncol. 29, 1221–1227 (2011).

    Article  CAS  PubMed  Google Scholar 

  7. Stopeck, A. T. et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J. Clin. Oncol. 28, 5132–5139 (2010).

    Article  CAS  PubMed  Google Scholar 

  8. Cummings, S. R. et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N. Engl. J. Med. 361, 756–765 (2009).

    Article  CAS  PubMed  Google Scholar 

  9. Shane, E. et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J. Bone Miner. Res. 25, 2267–2294 (2010).

    Article  PubMed  Google Scholar 

  10. Body, J. J. et al. Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposure. J. Bone Miner. Res. 25, 440–446 (2010).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Orthopaedic Surgery and Physiology and Biophysics, University of Arkansas for Medical Sciences, 4301 West Markham Street, Little Rock, 72205, AR, USA

    Larry J. Suva

  2. Departments of Hematology and Oncology, University of Arkansas for Medical Sciences, 4301 West Markham Street, Little Rock, 72205, AR, USA

    Brooke E. Brander & Issam Makhoul

Authors
  1. Larry J. Suva
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Brooke E. Brander
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Issam Makhoul
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Larry J. Suva.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Suva, L., Brander, B. & Makhoul, I. Update on bone-modifying agents in metastatic breast cancer. Nat Rev Endocrinol 7, 380–381 (2011). https://doi.org/10.1038/nrendo.2011.80

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrendo.2011.80

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer